Business Wire

Covetrus Announces Changes to Senior Management Team

Share

Covetrus™ (NASDAQ: CVET), a global leader in animal-health technology and services, today announced several changes to its senior management and regional leadership teams.

Effective January 7, 2020, Mike Ellis has been promoted to executive vice president and will add North America to his existing responsibilities as the leader of Europe. David Hinton has been promoted to executive vice president and will add global sourcing to his existing responsibilities as the leader of APAC & Emerging Markets. Georgia Wraight has been promoted to executive vice president and will continue to lead Covetrus’ Global Technology Solutions organization, which was formed in November 2019 following the combination of the company’s Global Software Services and Global Prescription Management business units. Matthew Leonard will transition into an advisory role and depart as the company’s global supply chain officer and executive vice president and president, North America.

In addition to these senior management team changes, the company is also introducing a new organizational framework in Europe that centralizes the larger regions into three geographic groupings – Northern Europe, Central Europe and Central Eastern Europe – to simplify operations to better meet the needs of customers and manufacturer partners.

  • Northern Europe, which includes the United Kingdom, Ireland and France, will be led by Jamie Tattersfield, vice president, Northern Europe. Jamie most recently served as the managing director of Covetrus United Kingdom and has had roles within the U.K. veterinary supplies business, including at legacy W. & J. Dunlop Ltd. (“Dunlops), for more than 30 years.
  • Central Europe, which includes Germany, Switzerland, Austria, Netherlands and Belgium, will be led by Thomas Friedl, vice president, Central Europe. Thomas most recently served as the managing director of Covetrus’ DACH region and has had a number of roles of increased responsibility in the animal health and medical device industries over the last 25 years.
  • Central Eastern Europe, which includes Poland, Czech Republic, Slovakia and Romania, will be led by Karolina Brodziak, vice president, Central Eastern Europe. Karolina most recently served as the managing director of Covetrus Poland and has had a number of roles within the company’s Polish distribution business of animal health products and services, including at Medivet, for approximately 20 years.

The vice president of each geographic grouping as well as the managing director of Covetrus’ Spain and Portugal business will report to Mike Ellis.

Covetrus is also announcing the hiring of Simon Hellams, effective February 12, 2020, to serve as vice president and managing director, Australia and New Zealand (ANZ). Simon has had a number of successful leadership positions over the last two decades in both the animal health and agribusiness sectors in the ANZ region, including for Ruralco Holdings, Boehringer Ingleheim and Merial. Simon will report to David Hinton.

About Covetrus

Covetrus is a global animal-health technology and services company dedicated to empowering veterinary practice partners to drive improved health and financial outcomes. We’re bringing together products, services and technology into a single platform that connects our customers to the solutions and insights they need to work best. Our passion for the well-being of animals and those who care for them drives us to advance the world of veterinary medicine. Covetrus is headquartered in Portland, Maine, with more than 5,500 employees, serving over 100,000 customers around the globe. Learn more at covetrus.com.

Forward-Looking Statements

This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including statements about our future financial and operating results including 2019 guidance, and other matters. We may, in some cases use terms such as "predicts," "believes," "potential," "continue," "anticipates," "estimates," "expects," "plans," "intends," "may," "could," "might," "likely," "will," "should" or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous risks and uncertainties, including but not limited to, risks associated with our management transition; the ability to successfully integrate operations and employees; the ability to realize anticipated benefits and synergies of the transactions that created Covetrus; the potential impact of the consummation of the transactions on relationships, including with employees, customers and competitors; the ability to retain key personnel; the ability to achieve performance targets; changes in financial markets, interest rates and foreign currency exchange rates; changes in our market; the impact of litigation; the impact of Brexit; and those additional risks and factors discussed, including those discussed under the heading "Risk Factors" in our Annual Report on Form 10-K filed on March 29, 2019 and Quarterly Report on Form 10-Q filed for the quarter ended September 30, 2019, and in our other SEC filings. Our forward-looking statements are based on current beliefs and expectations of our management team and, except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise. Investors are cautioned not to place undue reliance on these forward-looking statements.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Nicholas Jansen, Investor Relations
nicholas.jansen@covetrus.com | (207) 550-8106

Kiní Schoop, Public Relations
kini.schoop@covetrus.com | (207)550-8018

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 22:00:00 EET | Press release

Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar

SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 21:35:00 EET | Press release

SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support of the optics and photonics community and mentorship of others. “It’

Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 21:00:00 EET | Press release

Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus

ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 20:30:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026, from 8:57- 9:07 a.m. PST. HERIZON-GEA-01 met the dual primary endpoint of progression-free survival (PFS), demonstrating statistically significant and clinically meaningful improvements in both experimental arms compared to the control arm. The addition of TEVIMBRA to ZIIHERA and chemotherapy also sho

Siemens and NVIDIA Expand Partnership to Build the Industrial AI Operating System6.1.2026 19:07:00 EET | Press release

CES 2026 - Siemens and NVIDIA today announced a significant expansion of their strategic partnership to bring artificial intelligence into the real world. Together, the companies aim to develop industrial and physical AI solutions that will bring AI-driven innovation to every industry and industrial workflow, as well as accelerate each others’ operations. To support development, NVIDIA will provide AI infrastructure, simulation libraries, models, frameworks and blueprints, while Siemens will commit hundreds of industrial AI experts and leading hardware and software. “Together, we are building the Industrial AI operating system – redefining how the physical world is designed, built, and run - to scale AI and create real-world impact,” said Roland Busch, President and CEO of Siemens AG. “By combining NVIDIA’s leadership in accelerated computing and AI platforms with Siemens’ leading hardware, software, industrial AI and data, we’re empowering customers to develop products faster with the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye